'#$)16.
TargetIdentifica
tion &Validation

Lead
Discovery&Optimizati
onPreclinicalStudies

Clinical
TrialsRegistration / Review/ Approval!"78 

3/40+ Launch &Commercia
lization

Lifecycle
Management

78&%

26-0+5,"RWD*(16.

/>H;>H;

,%&,/(%&C<E=2H )+"*I J!

"*!



AH6=2G5$#IJ.-'


@0HA7?8DG9+B>24F1@31H:
+'++B>24F1@31H:  ⇆ ⇆ ⇆ ⇆ ⇆   PA)'!(1&23(1&+1$-( /*1%(MA)VM*1,")#.0$(PV) 5)SASBusinessIntelligencePlatformTUXa

0 ^g]OQdhS
238*G0 )1
122*G)1(Oracle DB)$ ,64*G,6$ :1C
27*G'/:1

Electric Data
Capture (EDC)Ø3G.7M8&B>
KdfiTc[eYiV`iUM%2=

GYiV)<!<"5<#9EDG4;$
Client PC1
77*G1*293SASBI server

Clinical Data
Warehouse (CDW)GYiVFFPW^YiZ?LKØ@JAG+*0 Hb\iRE;(-B&?LK=l(lll*l

SyyyC

yyyyayayyyDlm

Sm

Sym
M

mm

yecym

SgyDM

2141 2 * 64 /3/46
7 6/3gS
32•isS•ecltn9476666eec) 97/ 2ee68 7/ 29t3ee( 97 / 281

97 / 281(( 97/ 2)84(81çýãÚ÷ýêûÛ

バイバイオバンク第1コホート、
日本大学登録症例：N=18,819 、
ﬁle: Cd_sum、
バンク第1コホート登録症例数’共通のみ’登録患者、
N=43
ﬁle: 、

バイバイオバンク第1コホート、
日本大学登録症例：N=18,776 、
ﬁle: Cd_sum、
バンク第1コホート登録症例数

非癌疾患登録患者(癌登録患者を除く)、
N=14,714
ﬁle: Cd_non_cancer、癌13疾患登録患者、
N=4,062
ﬁle: Cd_13cancer、

日大病歴データベースと連携、
ﬁle: Om_b_ref、

非癌疾患登録患者(癌登録患者を除く)、
N=14,704
ﬁle: Om_b_non_cancer、

登録日以降に癌病歴のある患者（癌病名のみ選択、）
N=8,554
ﬁle:Test1、³    Nihon University School of Medicine Clinical Data Warehouse: NUSM's CDW103 ($*, )'!"219"
2 344
&2

1#800 ( )'!"233"
21,037
&2.18%/1
2,252.6)1
846.9)-+  )'!"217"
2409
&2.18%/1
1,226.6)1
320.60110

!

$"NUSM's CDW (" '&(60 (23(#20#N=34,661

21%(#20#N=2,070
50.5

50

43.6

40
30.8
26.5

30
20

15.612.4

100

6.8 7.2
1.0 0.320)29

2.9 2.430)3940)49"'(50)5960)6970"%##  (')

NUSM's CDW ( 23 )$20$N=36,516
 ( 21&!)$20$N=806
50
45
40
35
30
25
20
15
1050

42.4
40.7
32.9
26.1

14.7 14
10.4
2.6

5.5
1

20*29

5.8

3.8

30*3940*49
#()50*5960*697045

$"NUSM's CDW ( 23(#20#N=11,177
 ( 21 %!(#20#N=443
40.2 39.7

40

35.4

"  '&(3530
25.3

2520
13.9

15

10.6

1050

15.3

7.0

6.7
3.3
0.520)29

2.030)3940)49"50)59'(60)6970Retrospective cohort study

EFFECTS OF STATIN ON NEW-ONSET DIABETES IN SUBGROUPS.
• In a total of 12,177 Japanese patients without diabetes, from December 2004 to November 2012, weidentified 500 statin users and 500 matched non-users using propensity-score matching.
• Patients were followed until December 2017.
• We estimated the hazard ratios of new-onset diabetes associated with statin use among patients withvarious medical histories and current medications.
Subgroup

No. of patients

Statin users

Non-users

Hazard ratio (95% CI)

All patients1000

No. of events (%)
78 (15.6)
48 (9.6)

1.61 (1.10-2.37)

Ischemic heart disease217

29 (25.2)

12 (11.8)

2.28 (1.11-4.66)

Other heart disease213

25 (22.3)

12 (11.9)

1.59 (0.78-3.24)

Liver disease136

4 (5.9)6 (8.8)1.45 (0.65-3.27)

Hypertension

450

44 (18.9)

26 (12.0)

1.57 (0.87-2.81)

Antihypertensive drug

410

39 (18.1)

22 (11.3)

1.31 (0.78-2.21)

Antithrombotic drug375

36 (19.8)

26 (13.5)

1.40 (0.80-2.43)

NSAID

260

24 (18.6)

17 (13.0)

1.57 (0.77-3.21)

H2 blocker

135

14 (23.3)

9 (12.9)

1.38 (0.52-3.70)

Proton pump inhibitor171

26 (28.3)

10 (12.7)

2.95 (1.36-6.39)

Antiarrhythmic drug

91

8 (17.8)

5 (10.9)

1.03 (0.28-3.81)

Medical history

Medication

0.1

110

• In patients with various clinical backgrounds, those who received statin therapy
had a higher risk of new-onset diabetes than those who did not receive it.
BMC Pharmacol Toxicol. 2019 May 28;20(1):34

１秒率は、肺機能を調べる指標の一つです。
深く息を吸って一気に吐き出した空気量（これを努力性肺活量といいます）に対し、最初の1秒間で吐き出した量（1秒量）の割合を示したものです。70％以上が正常ですが、1秒率が低下している場合は閉塞性換気障害（気管支が狭くなっているために起こる呼吸機能障害）が疑われます。
閉塞性換気障害には、気管支ぜん息や慢性閉塞性肺疾患（COPD）などがありますが、どの疾患も気管支が狭くなっているので、一気に息を吐き出すことができず1 秒率が低下するのです。つまり呼吸しにくい状態であることを意味しています。

16

=?D>@CF+@?A?E=E?CBnh`fGINHJMP+JIKIOGOIMLnh`-B<8/973.+fSlTgdT3,DM

4/994

6302

B41B3-,.
3/9;8 860:

*

4/643

570;

3/777 8604

955

3305

6:: 8808

4/;82

7:09

3/;35 8608

$"{(c!ZmaTB4Sk|vqtwropysxzue)'[lf&XfWGINHJMP+JIKIOGOIMLn_aVkQ]fU^f~%fgi f!nUYaVj\Q d}17}
 #bSlR

Cross-sectional study

ASSOCIATION OF MEDICAL HISTORY WITH AIRFLOW LIMITATION (AL)
• A total of 11,898 Japanese patients aged ≥40 years old, who underwent spirometry tests, comprisingpatients with airflow limitation (n=2,309) or without airflow limitation (n=9,589).
• The relationship between the presence of airflow limitation and a medical history of 22 categories ofdiseases, was assessed. The model was adjusted for age, sex, BMI, and pack-years of smoking.
Patients without AL

Patients with AL(n=9,589)(n=2,309)

Medical history

Adjusted odds ratio (95% CI)
Number (%)

Pulmonary tuberculosis

319 (3.3%)

204 (8.8%)

1.72 (1.39-2.11)

Primary lung cancer

573 (6.0%)354 (15.3%)

1.50 (1.28-1.77)

Myocardial infarction

441 (4.6%)

205 (8.9%)

1.22 (1.01-1.48)

Heart valve disorder

706 (7.4%)

296 (12.8%)

1.33 (1.14-1.56)

Arrhythmia

892 (9.3%)

359 (15.6%)

1.19 (1.03-1.38)

Heart failure528 (5.5%)274 (11.9%)

1.53 (1.29-1.81)

0.1

110

• A history of heart disease, including myocardial infarction, heart failure, arrhythmia, and heart valve
disorder, in addition to tuberculosis or primary lung cancer, was significantly associated with thepresence of airflow limitation.
Int J Chron Obstruct Pulmon Dis. 2017;12:2363-2371

Retrospective observational study+!(;57BIY[FKPX\L2*0<DZOSEV\$"*<• -aIY[FKPX\L2*^ChEIbQRUJZ / `GX[MW[)%/ `?9=YTKNHW[_C89(^545_3• 052.1;57B $"*^$"*`4:*`*`5@>*_( <#C,893
IY[FKPX\L2*';57B $"*(<<&#(^]_3530

$"*4:*25å*20

*15
10
50-60

-40-200204060

IY[FKPX\L2*06A<.
Therapeutic Research 38(10) 979-991 2017@TKALNOLIGOE0)7P$ ===QP:2002.1.1U2016.12.31Q→(RS:200311='#?%9150
100No1'#-$6BKFJHOGD

MCOI
DB
10,600717;&

ALT(GPT)

50%9@ $'#*.$>@
<3 $<,3$
B +!
<83$

0800
600

1"/!

AmylaseDB1165
962

400
200
010

HbA1c

4DB
105#

864
2002

2004

2006

2008

2010

5:P2003U2016Q

2012

2014

2016

2018






10

*&/No0

HbA1c

864
2002

2004
*'-.40mg/2006

2008

2010
&*/+3mg/2012

2014

2016

&*/+1mg/100mg/%)!6u/,/ 20u/+ 5mg/)/CR40mg/#-$,8mg/+(40mg/"+).2mg/23514'+80mg/$,.30mg/$,.10mg/2018

$ :LP;(=N HT1draN
VG?SAP HANANST>8%V$GI:dragbe
prZV -G?:O*+.E*+6.O^Znrfq[R*+\r_O$05siXr]hncX^adXtV2C& E
JKBT@FUV:O*+.RIN-HT/jo[mkE#'HTFMV 0MH
T7"0sdrahlrO4?!<,%?WZ`^NHT)"0?`YlncX3OtDSQ9',%O -LAT@

23

.

-0,24.

-0,99--.

.
-5 ,380.
-4 ,610.

25

0- .74=
0- .7486235,
16235 ,

35

26

0. 8

45HA C

659

HA59,
20 . 8
459 ,
27=
HA C
6 3
27

1-1900.

1950 200028

71900-.

1950
(7005

12000

29

61900-1.

1950
(70071970
(5062000
30

-



2.1



31

-.

2

1

1

HbA1c  RWD32







NUSM’s CDW&*|nsevtrkdho`*xmyj "2|=;;?<<!<x-|

=;<;@!>;HBD,|nsevtrkdho8HBD9 <PN:LJYa=PN:LJY ^.`3.c*[\5/),| .`3.c*[\5/xCXSRUWTM"2|0.<>~b]
xqlkwf|igd8STRSMQUOVY7UKRTM|FG{qlkwf
zFG_a6Z Z%Z>D `.x/'$#4+|/(eudkpwZAIEZ1Z}Z%c*{TCM,(1mg/day or 2mg/day)Baseline"2TCM`3.

Control,
Baseline"2

`3.
33

Baseline:2M
33

Exposure:1~3M

 MRP434
 

NUSM’S CDWWGN@QOME=CH:

200411X201079.(<564731;20:0)!&N=28,647

TCM<564731;&N=1,404

TCM<5647382&N=27,243

PS matching
TCM 1mg/day
N=99

Control for
TCM 1mg/day
N=99

Exclude:TCM:. (:?N>L* :
IGN>L* :"/#(:#-3SBRGQTO':$)@P=EJR≥2mg/dl(TCM%V
TCM#-14+-:,

PS matching
TCM 2mg/day
N=61

Control for
TCM 2mg/day
N=61
TCM: GN@QOME=CH
PS matchingWpropensity score matchingU
DB=KFERAV

35 

ΔCreatinine (μmol/L)

0.60.40.2

604201 mg"602 mg

1 mg(daily dosage)

2 mg

40200-201 mg

2 mg


0.2

Δpotassium (mmol/L)

0.6

ΔSodium (mmol/L)ΔUric acid (μmol/L)

ΔUrea nitrogen (mmol/L)

0.8

0.2
-0.2
-0.6
-1-1.4

8

1-0.2

!

0.1

Trichlormethiazide

0Control

-0.1
-0.2

"
1 mg

2 mg

-0.3

1 mg

2 mg
36

Δ indicates the change in mean serum value during exposure period from baseline. *P<0.01( TCM 2mg/ day vs. Control)

Takahashi Y, Nishida Y, Nakayama T, Asai S. Cardiovasc Diabetol. 2011, 10:45

^iUkjg]OY_VPOWP_'

-6F#",0.<`^iQf.$<<:<< <%</9<SiQf.$<* <)<71( <(+ABC^hlZdm\mMRP4(ABCC4)
-H bk[e_EVPOWP_?nMRP4GKM5 23N AnOkc
iamjERTXcia mj?MRP4NAD5 N4BM@E> Lnbk
[e_EVPOWP_GKM;5. $n=KIOkciamjGKM58# EJGnMRP4?CH#!EFM@EN&37

Takahashi Y et al. Cardiovasc. Diabetol.2011.10:45
3838

39  403-yw~|tzsux B2IVUZY5MYV^R[\V]`5KPUZZW5ZS5HRQVPVYR5DWVYVPNW5EN]N5HNYNTRXRY]5K`\]RXC5IMKHb\5DEHK:9 %4+k{qh! f*;9 1$'j$ywljpqvu c #d/
<9 :>jywj.(=9 "d,d dhgmpqvu ,>9 -r}ljpqvu JRPNWW ?9 e-&)ino-r}pqvu@9 yw0jGYZ_8FZ_A9 JRTV\][`8ON\RQ5JNYQZXVaRQ5DWVYVPNW5L[VNW56JJDL7   asai.satoshi@nihon-u.ac.jp) 41

42